scholarly journals Structural and molecular basis for Ebola virus neutralization by protective human antibodies

Science ◽  
2016 ◽  
Vol 351 (6279) ◽  
pp. 1343-1346 ◽  
Author(s):  
J. Misasi ◽  
M. S. A. Gilman ◽  
M. Kanekiyo ◽  
M. Gui ◽  
A. Cagigi ◽  
...  
1983 ◽  
Vol 48 (3) ◽  
pp. 627-632 ◽  
Author(s):  
J Kahlon ◽  
K Sugiyama ◽  
P Roy

2020 ◽  
Author(s):  
Charles D. Murin ◽  
Pavlo Gilchuk ◽  
Philipp A. Ilinykh ◽  
Kai Huang ◽  
Natalia Kuzmina ◽  
...  

SummaryAntibodies that target the glycan cap epitope on ebolavirus glycoprotein (GP) are common in the adaptive response of survivors. A subset is known to be broadly neutralizing, but the details of their epitopes and basis for neutralization is not well-understood. Here we present cryo-electron microscopy (cryo-EM) structures of several glycan cap antibodies that variably synergize with GP base-binding antibodies. These structures describe a conserved site of vulnerability that anchors the mucin-like domains (MLD) to the glycan cap, which we name the MLD-anchor and cradle. Antibodies that bind to the MLD-cradle share common features, including the use of IGHV1-69 and IGHJ6 germline genes, which exploit hydrophobic residues and form beta-hairpin structures to mimic the MLD-anchor, disrupt MLD attachment, destabilize GP quaternary structure and block cleavage events required for receptor binding. Our results collectively provide a molecular basis for ebolavirus neutralization by broadly reactive glycan cap antibodies.


Cell Reports ◽  
2018 ◽  
Vol 24 (7) ◽  
pp. 1802-1815.e5 ◽  
Author(s):  
Natalia A. Kuzmina ◽  
Patrick Younan ◽  
Pavlo Gilchuk ◽  
Rodrigo I. Santos ◽  
Andrew I. Flyak ◽  
...  

2021 ◽  
Author(s):  
Pavlo Gilchuk ◽  
Charles D. Murin ◽  
Robert W. Cross ◽  
Philipp A. Ilinykh ◽  
Kai Huang ◽  
...  

AbstractEbolaviruses cause a severe and often fatal illness with the potential for global spread. Monoclonal antibody-based treatments that have become available recently have a narrow therapeutic spectrum and are ineffective against ebolaviruses other than Ebola virus (EBOV), including medically important Bundibugyo (BDBV) and Sudan (SUDV) viruses. Here we report the development of a therapeutic cocktail comprising two broadly neutralizing human antibodies rEBOV-515 and rEBOV-442 that recognize non-overlapping sites on the ebolavirus glycoprotein (GP). Antibodies in the cocktail exhibited synergistic neutralizing activity and resisted viral escape, and they were optimized for their Fc-mediated effector function activities. The cocktail protected non-human primates from ebolavirus disease caused by EBOV, BDBV, or SUDV with high therapeutic effectiveness. High-resolution structures of the cocktail antibodies in complex with GP revealed the molecular determinants for neutralization breadth and potency. This study provides advanced preclinical data to support clinical development of this cocktail for pan-ebolavirus therapy.


Immunity ◽  
2018 ◽  
Vol 49 (2) ◽  
pp. 204-206
Author(s):  
Sonja M. Best ◽  
Heinz Feldmann

Author(s):  
Ben O. Spurlock ◽  
Milton J. Cormier

The phenomenon of bioluminescence has fascinated layman and scientist alike for many centuries. During the eighteenth and nineteenth centuries a number of observations were reported on the physiology of bioluminescence in Renilla, the common sea pansy. More recently biochemists have directed their attention to the molecular basis of luminosity in this colonial form. These studies have centered primarily on defining the chemical basis for bioluminescence and its control. It is now established that bioluminescence in Renilla arises due to the luciferase-catalyzed oxidation of luciferin. This results in the creation of a product (oxyluciferin) in an electronic excited state. The transition of oxyluciferin from its excited state to the ground state leads to light emission.


Sign in / Sign up

Export Citation Format

Share Document